Biomarkers Industry Data Book - Cardiac Biomarkers, Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Neurological Biomarkers Market

Download Sample Copy@ https://tinyurl.com/3r28tf...

The global biomarkers markets combine to account for USD 41.62 billion revenue in 2021, which is expected to reach USD 137.76 billion by 2030, growing at a cumulative rate of 14.2% over the forecast period. The combination bundle is designed to provide a holistic view of these highly dynamic market spaces.

The global cardiac biomarkers market was valued at USD 13.98 billion in 2021 and is anticipated to witness growth at a rate of 14.7% over the forecast period. CVDs are one of the main causes of death globally, and hypertension & its pathological adverse effects pose a significant risk for other cardiac diseases, such as heart failure & stroke. Identifying early-stage biomarkers of hypertension and other CVDs is of high significance in predicting & preventing major mortality & morbidity related to these diseases. In addition, new research is focused on discovering second-generation biomarkers for CVDs. Constant advancements in this field to discover novel biomarkers are anticipated to boost segment growth.

#BiomarkersIndustry #FutureOfBiomarkers #BiotechInnovation #PrecisionMedicine #DiagnosticAdvancements #HealthcareTechnology #PersonalizedMedicine #BiomarkerResearch #MedicalBreakthroughs #DiseaseDetection

Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030

Download Sample Copy@ https://tinyurl.com/3atsyb...

The global neurodegenerative disease markets combine to account for USD 8.33 billion revenue in 2021, which is expected to reach USD 28.15 billion by 2030, growing at a cumulative rate of 15.6% over the forecast period. The combination bundle is designed to provide a holistic view of these highly dynamic market spaces.

Competitive Landscape
Competitive rivalry in this market is likely to be high due to increasing number of mergers, acquisitions, and partnerships undertaken by major players globally. Many established and clinical-stage pharmaceutical companies are involved in the development of novel therapies & drugs to target people with unmet clinical needs. Furthermore, the companies are focusing on the development of strategic alliances and research collaborations with competitors. For instance, in January 2022, Mindset Pharma Inc. and McQuade Center for Strategic Research and Development, LLC entered into a partnership to promote the advancement of psychedelic medications.

Some of the key players in the neurodegenerative disease industry are Eisai Co., Ltd., AbbVie Inc. (Allergan Plc.), Merck & Co., Inc., Adamas Pharmaceuticals, Inc., Novartis AG,H. Lundbeck A/S, Cerevel Therapeutics, Biogen, Daiichi Sankyo Company, Limited, F. Hoffmann La Roche Ltd., TauRx Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., AC Immune, Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc. (GSK). Key players in the market adopt this strategy to strengthen their product portfolio and offer diverse, technologically advanced, & innovative products to patients. For instance, in August 2022, Knight Therapeutics, Inc. re-launching Exelon (Rivastigmine) developed by Novartis after receiving marketing authorization in Brazil. This launch is expected to boost the Alzheimer’s therapeutics market in Latin America.

#NeurodegenerativeTherapeutics #NeurodegenerativeDiseases #TherapeuticInnovations #FutureOfNeurodegenerativeTherapeutics #NeurologicalDisorders #PrecisionMedicine #ResearchBreakthroughs #PatientCare #ClinicalTrials #DiseaseModifyingTherapies

Healthcare and AI: From Data to Diagnosis!

AI is creating smarter healthcare choices by enabling early diagnosis and customized treatment approaches.

Tap to see what possibilities are available https://bit.ly/3TAZDhL

#aiinhealthcare #aihealthcare #ArtificialIntelligence #AIDevelopmentCompany #healthcareai #aiandhealthcare #MedicalAI #aihealthcare #HealthTech #MedTech #HealthAI #InnovativeMedicine #PrecisionMedicine #DigitalHealth #AIinMedicine #Innovation #startups #entrepreneur

The global market for precision medicine (PM) is anticipated to increase from USD 69 billion in 2023 to reach USD 150 billion in 2030 registering a CAGR of 11 percent finds Jasper Colin’s market research study.

Explore our most recent study, "Regulations are Crippling Precision Medicine," to learn more about the obstacles preventing this revolutionary sector from expanding.

https://www.jaspercolin.co...

#HealthCare #pharmaceuticals #chemotherapy #BreastCancerAwareness #PrecisionMedicine

The global #life #science #microscopes industry generated over USD 3.35 billion in 2021 and is expected to grow at a CAGR of 8.9% over the forecast period. These microscopes find their applications in a wide array of life science applications such as clinical diagnostics, drug discovery, minimally invasive surgical procedures, advanced therapies such as gene & immune therapies, IVF, and others. Super resolution microscopy used for plant & human cell research, gene therapy, and other life cell imaging held the largest share of life science microscopes revenue.

Download Sample Copy@ https://cutt.ly/0w1x7Itw

The rapid growth of minimally invasive surgeries and the usage of microscopes in these surgeries is a pivotal factor attributing to the rapid growth of surgical microscopes globally. Within the surgical applications, ENT and plastic & reconstruction surgeries will witness a CAGR of nearly 10% in the coming years. Leica Microsystems, Carl Zeiss Meditec AG, Olympus Corporation, and Nikon Corporation are some of the key players spearheading the growth of these applications.
|

#MicroscopeRevolution #LifeScienceInnovation #MicroscopicAdvancements #ScientificBreakthroughs #ImagingTechnologies #BiomedicalResearch #PrecisionMedicine #CellularExploration #MicroscopyRevolution #DiscoveringTheInvisible